Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL2027719 | 1.00 | NPSR1 (0.42) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| Potassium Ion SCHEMBL2052541 | 1.00 | NPSR1 (0.42) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL8382034 | 0.79 | — | — | |
| SCHEMBL265673 | 0.79 | — | — | |
| Potassium Ion SCHEMBL29000372 | 0.79 | NPSR1 (0.44) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL27385701 | 0.78 | NPSR1 (0.47) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL4115120 | 0.78 | NPSR1 (0.47) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL4115115 | 0.78 | NPSR1 (0.47) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL3710533 | 0.77 | — | — | |
| SCHEMBL3192124 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688159-A1 | PARG INHIBITORY COMPOUNDS | FoRx Therapeutics AG (CH) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025133396-A1 | NOVEL BICYCLO HETEROARYL PARG INHIBITORS | FORX THERAPEUTICS AG (CH) | 2025-06-26 | — | — | WO | disclosed |
| EP-4313293-B1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARM SPA (IT) | 2025-05-07 | — | — | EP | disclosed |
| EP-4506349-A2 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2025-02-12 | — | — | EP | disclosed |
| US-20240425498-A1 | PARG INHIBITORY COMPOUNDS | FORX THERAPEUTICS AG (CH) | 2024-12-26 | — | — | US | disclosed |
| US-20240391936-A1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-11-28 | — | — | US | disclosed |
| WO-2024209035-A1 | PARG INHIBITORY COMPOUNDS | FORX THERAPEUTICS AG (CH) | 2024-10-10 | — | — | WO | disclosed |
| EP-4413001-A1 | PARG INHIBITORY COMPOUNDS | FoRx Therapeutics AG (CH) | 2024-08-14 | — | — | EP | disclosed |
| WO-2023057389-A1 | PARG INHIBITORY COMPOUNDS | FORX THERAPEUTICS AG (CH) | 2023-04-13 | — | — | WO | disclosed |
| WO-2011079076-A1 | SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1, 2-A]PYRIDINE-3- CARBOXAMIDE COMPOUNDS AS CFMS INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391936-A1 | TETRAHYDROTHIENO PYRIDINE DERIVATIVES AS DDRS INHIBITORS | DDR1, DDR2, DDRGK1 | NPSR1 2651/4885GLO1 4008/4885ALDH1A1 3941/4885 |
| US-20240425498-A1 | PARG INHIBITORY COMPOUNDS | PARG, PLG, PPIG | NPSR1 2456/4885GLO1 1871/4885ALDH1A1 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.